273 related articles for article (PubMed ID: 38183744)
1. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
3. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
4. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
5. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
7. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
[TBL] [Abstract][Full Text] [Related]
8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
11. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
12. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract][Full Text] [Related]
13. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
17. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
20. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
